Nath Bio-Genes (India) Ltd Q2 Profit Falls 85.7% to ₹0.4 Crore
Key highlights
- Nath Bio-Genes reported Q2 FY27 net profit of ₹0.4 crore, down 85.7% year on year.
- Q2 FY27 revenue from operations was ₹40.7 crore, down 7.1% from ₹43.8 crore a year earlier.
- Operating margin declined to 3.2% in Q2 FY27 from 7.8% in Q2 FY26.
- H1 FY27 operating cash flow was negative ₹3.59 crore, while the reported H1 net loss was ₹7.61 crore.
powered by IRIS
Nath Bio-Genes (India) Ltd reported Q2 FY27 net profit of ₹0.4 crore, down 85.7% year on year from ₹2.8 crore, while revenue from operations fell 7.1% to ₹40.7 crore for the quarter ended September 30, 2026. The result indicates a sharp decline in quarterly profitability despite a reported exceptional item.
Know Nath Bio-Genes (India) inside out
Results, valuation, peers and who's buying, in one view.
What did Nath Bio-Genes report for Q2 FY27?
Nath Bio-Genes (India) reported revenue from operations of ₹40.7 crore and net profit of ₹0.4 crore in Q2 FY27. Revenue was lower than ₹43.8 crore in Q2 FY26, while net profit declined from ₹2.8 crore in the corresponding quarter a year earlier.
The company reported profit before exceptional items and tax of a loss of ₹0.5 crore, compared with a profit of ₹3.4 crore in Q2 FY26. Exceptional items of ₹1.8 crore lifted reported profit before tax to ₹1.3 crore. Net profit after tax stood at ₹0.4 crore.
The results were approved at the board meeting scheduled for November 14, 2026, for unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026. The figures cited in the quarterly results summary are consolidated figures.
How did the September quarter compare with earlier periods?
Nath Bio-Genes' Q2 FY27 revenue was 7.1% lower year on year and substantially below the ₹328.4 crore reported for Q1 FY27 in the results summary. Net profit declined 85.7% year on year and 98.8% sequentially from ₹32.3 crore in Q1 FY27.
Operating margin was reported at 3.2% in Q2 FY27, compared with 7.8% in Q2 FY26 and 10.0% in Q1 FY27. The company defines operating profit as excluding other income. The reported year-on-year operating-profit decline was 253.3%, reflecting a move from an operating profit in the year-earlier period to an operating loss in the latest quarter.
Other income was ₹1.8 crore, compared with ₹1.9 crore in both Q1 FY27 and Q2 FY26. This limited variation means that the lower revenue and weaker operating performance were central to the change in quarterly profit.
What do the half-year financial disclosures show?
The half-year disclosures show a reported net loss of ₹7.61 crore and negative operating cash flow of ₹3.59 crore. These figures provide additional context for the quarterly result because they point to pressure on earnings and cash generation during the first half of FY27.
On a standalone balance-sheet basis, total equity stood at ₹90.35 crore at the half-year stage, compared with ₹97.95 crore on March 31, 2026. Inventories were ₹54.62 crore, lower than ₹71.82 crore at the end of March. Current borrowings were ₹19.04 crore, and the company disclosed new non-current borrowings of ₹2.69 crore.
The limited-review reports carried an unmodified conclusion, according to the filing summary. CARE Ratings also reported no deviation from the stated IPO objects for the half-year ended September 2026.
Got a follow-up? Ask IRIS
Why does the quarterly profit decline matter to investors?
The Q2 result matters because profit contracted more sharply than revenue. A 7.1% year-on-year fall in revenue was accompanied by an 85.7% fall in net profit, and profit before exceptional items and tax turned negative. This indicates that the quarter's reported profit was supported by the ₹1.8 crore exceptional item rather than by operating performance alone.
For investors, the reported 3.2% operating margin is also relevant because it was below both the 7.8% margin in Q2 FY26 and the 10.0% margin in Q1 FY27. The company had reported FY25 revenue of ₹91.37 crore, operating profit of ₹18.27 crore, and net profit of ₹10.7 crore. The latest quarterly and half-year figures therefore provide a different near-term earnings and cash-flow picture from that annual base.
The reduction in inventories may be relevant to working-capital monitoring, while the disclosed borrowings and negative operating cash flow remain important balance-sheet data points. The filing does not provide a numerical forecast, so no conclusion on future revenue, margins, or profitability can be drawn from these results alone.
What is Nath Bio-Genes' next disclosed event?
Nath Bio-Genes has scheduled its Q2 and H1 FY27 earnings call for November 16, 2026, at 4:00 PM IST. Go India Advisors will host the call, with Managing Director Satish Kagliwal and Chief Financial Officer Amol Gupta set to participate.
The call may provide management's explanation of the quarterly revenue movement, margin compression, exceptional items, working-capital changes, and half-year cash flow. The earnings-call intimation itself did not contain financial results or guidance.
Conclusion
Nath Bio-Genes (India) recorded a weak Q2 FY27 profit outcome, with net profit falling to ₹0.4 crore despite a ₹1.8 crore exceptional item. Revenue declined modestly year on year, but the movement in operating profitability was more pronounced, while half-year disclosures showed a net loss and negative operating cash flow.
Investors will next watch the November 16 earnings call for management's comments on the September-quarter performance, inventory reduction, borrowings, and cash flow. The company has not disclosed a forward financial target in the provided filings, leaving these operational details central to the next update.